With simultaneous application with digitalis drugs increases the risk of arrhythmia and testosterone sustanon a magnesium-containing medications (eg, antacids) – increases the risk of gipermagniemii, in connection with which these funds should not be administered on hemodialysis patients receiving Osteotriol.
The use of drugs that are inducers of liver enzymes (phenytoin, phenobarbital, and others.), may cause an increase in drug metabolism and decreased calcitriol concentrations in blood serum, and therefore, while the application and these drugs may require a higher dose of calcitriol.
Kolestiramin can reducing intestinal absorption of fat soluble vitamins and including calcitriol.
Application with thiazide diuretics may increase the risk of hypercalcemia.
in applying because of the risk of hypercalcemia are not allowed other co-administration of vitamin D and its derivatives.
During treatment should not be given other drugs of vitamin D, including its derivatives. It should also consume a significant amount of food products enriched with vitamin D (butter, eggs, etc.).
In the period of testosterone sustanon treatment is necessary to regularly monitor the level of calcium and inorganic phosphate in the blood plasma and urine, especially in patients with renal osteodystrophy, and located on the prolonged bedrest (particularly after surgery).
in order to prevent hypercalcemia dosage calculated based on the patient’s response to the drug and chosen individually. The effectiveness of the treatment provided by the definition of an adequate daily dose of calcium, including, if necessary, a change in diet, as well as the reception containing calcium supplements or drugs. By improving calcium absorption in the gastrointestinal tract, some patients receiving calcitriol can do low intake of calcium preparations, and in some cases (with a tendency to hypercalcemia) to dispense with their reception.
It is necessary to monitor the level of calcium in the serum for at least twice a week for period of use of the drug. In case of excess in the serum calcium level by 1 mg / 100 ml (250 μmol / L), compared with the accepted norm – 11.9 mg / 100 ml (2250 – 2750 μmol / l) or creatinine levels increase in blood serum to 120 μmol / l and above, receiving Osteotriola should be discontinued immediately. The resumption of treatment is allowed only after normalization of serum calcium levels within the allowable range using regulatory reduced to 0.25 ug dose. When concomitant administration of barbiturates or anticonvulsants may need to increase the dosage of calcitriol. In the early years of osteoporosis treatment is necessary to measure the concentration of calcium in serum creatinine within 4 weeks, 3 months and 6 months. At the end of the period necessary to carry out pilot tests of these parameters at intervals of 6 months.
Patients with normal renal function receiving Osteotriol should avoid dehydration, ensuring testosterone sustanon adequate intake of fluid.
Use during pregnancy
Application Osteotriola during pregnancy only if the expected benefit to the mother outweighs the potential risk to the fetus.